Checkpoint kinase 2 controls insulin secretion and glucose homeostasis

Area of Science:

• Endocrinology and Metabolism
• Molecular Biology
• Pharmacology

Background:

• Understanding insulin secretion regulation is crucial for metabolic diseases.
• Previous research has focused on known pathways, leaving potential novel mechanisms unexplored.

Purpose of the Study:

• To identify novel regulators of glucose-stimulated insulin secretion (GSIS).
• To investigate the therapeutic potential of identified compounds in diabetes models.

Main Methods:

• Chemical screening of compounds affecting human beta cell lines.
• In vitro testing on human islets (healthy and type 2 diabetic) and cynomolgus macaque islets.
• In vivo studies in diabetic mouse models and cynomolgus macaques.
• Genetic manipulation (CHEK2 ablation) and metabolic profiling.

Main Results:

• AZD7762 was identified as a potentiator of GSIS in human beta cells, islets, and macaques.
• AZD7762 improved glucose tolerance in diabetic mouse and macaque models.
• CHEK2 ablation increased insulin secretion, and Chk2-/- mice showed improved glucose clearance.
• The CHEK2-PP2A-PLK1-G6PD-PPP pathway was identified as critical for insulin secretion.

Conclusions:

• A novel pathway regulating insulin secretion, involving CHEK2, has been identified.
• This pathway is conserved across species and relevant in both healthy and type 2 diabetic conditions.
• AZD7762 represents a potential therapeutic agent for enhancing insulin secretion.